August 28, 2023 11:39 AM EDTUpdated 11:59 AM

Amgen says RNA heart drug has long-lasting effect as it races Novartis; Eli Lilly takes pill approach to same target: #ESC23

Lei Lei Wu

News Reporter

Amgen and Eli Lilly unveiled new data for their experimental heart drugs that target lipoprotein(a) — a cholesterol carrier that can increase the risk of heart …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen says RNA heart drug has long-lasting effect as it races Novartis; Eli Lilly takes pill approach to same target: #ESC23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Am­gen says RNA heart drug has long-last­ing ef­fect as it races No­var­tis; Eli Lil­ly takes pill ap­proach to same tar­get: #ESC23

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Amgen says RNA heart drug has long-lasting effect as it races Novartis; Eli Lilly takes pill approach to same target: #ESC23